MIIST305 - Ulcerative Colitis

MIIST305 – Ulcerative Colitis

Restoring mucosal tissue and innate gut barrier function

Inflammatory Bowel Disease (IBD) is a descriptive term for two main forms of chronic gut inflammation, mucosal disruption, and disintegration, known as ulcerative colitis (UC) and Crohn’s disease (CD). Studies suggest that chronic damage to the intestinal mucosal barrier, and consequent permeability changes that result in systemic inflammation, are key initiating and perpetuating elements in UC.

Synedgen, Inc. has developed MIIST305, a first-in-class immunomodulatory therapeutic that has been shown to effectively restore innate gut barrier function and that demonstrates restoration of a healthy gastrointestinal tract in preclinical models of colitis. MIIST305 is designed to restore the natural immune functions of the gastrointestinal surface and help to repair damaged, multilayered intestinal barrier in UC. As MIIST305 is not a systemic immunosuppressant and acts locally, it is not expected to cause the systemic immune compromise often observed with standard-of-care UC anti-inflammatory drugs and biologics.